2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with Benign Neoplasms in 48 studies
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " In GS-2 glioblastoma cells, PI3K inhibition by LY294002 or everolimus caused hyperpolarized lactate to drop to 42 +/- 12% and to 76 +/- 5%, respectively." | 3.76 | Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. ( Brandes, AH; Chaumeil, MM; Dafni, H; Haas-Kogan, DA; James, CD; Kurhanewicz, J; Nelson, SJ; Ronen, SM; Sukumar, S; Vancriekinge, M; Venkatesh, HS; Vigneron, DB; Ward, CS, 2010) |
| "Presently cancer is a grave health issue with predominance beyond restrictions." | 2.72 | Therapeutic progression of quinazolines as targeted chemotherapeutic agents. ( Bansal, R; Malhotra, A, 2021) |
| "Some of them revealed potent anticancer efficacy and are now undergoing clinical trials." | 2.44 | Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. ( Kong, D; Yamori, T, 2008) |
| "During the irradiation, the cancer cells treated with 0." | 1.43 | Invention of a novel photodynamic therapy for tumors using a photosensitizing PI3K inhibitor. ( Araki, N; Hayashida, Y; Ikeda, Y; Kakehi, Y; Kato, T; Kawai, K; Sawada, K, 2016) |
| "Side population (SP) cells within tumors are a small fraction of cancer cells with stem-like properties that can be identified by flow cytometry analysis based on their high ability to export certain compounds such as Hoechst 33342 and chemotherapeutic agents." | 1.40 | Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. ( Hu, Y; Huang, P; Ju, HQ; Liao, J; Liu, PP; Tang, ZJ; Wang, P; Wu, WJ; Xu, RH; Yang, J; Zeng, ZL, 2014) |
| "A key modality of non-surgical cancer management is DNA damaging therapy that causes DNA double-strand breaks that are preferentially toxic to rapidly dividing cancer cells." | 1.39 | Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and DNA repair inhibitors. ( Engelward, BP; Floyd, S; Ge, J; Huang, Q; Mutamba, JT; Rowland, EA; Weingeist, DM; Wood, DK; Yaffe, MB, 2013) |
| "We optimized the conditions for the cancer cell xenograft in terms of injected cell numbers, incubation temperature and time." | 1.38 | A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening. ( Chang, YT; Choi, SY; Jung, DW; Kim, CH; Oh, ES; Park, SH; Williams, DR, 2012) |
| "Survivin expression is elevated in cancer cells, and induced by some growth factors through PI3K activation." | 1.36 | Regulation of survivin by PI3K/Akt/p70S6K1 pathway. ( Jiang, BH; Liu, LZ; Liu, N; Meng, Q; You, YP; Zhao, P, 2010) |
| "In AZD6244-resistant cancer cells, we observed the impaired nuclear localization of FOXO3a, reduced FOXO3a-mediated transcriptional activity, and decreased the expression of FOXO3a target gene Bim after cell treatment with AZD6244." | 1.36 | Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. ( Andreeff, M; Chang, CJ; Du, Y; Engelman, JA; Hortobagyi, GN; Hung, MC; Wang, Y; Wong, KK; Xia, W; Yang, JY, 2010) |
| "In addition, treating Z12 or cancer cell lines with either of these 2 inhibitors significantly decreased their secretion of TGFβ2." | 1.36 | Activation of cAMP-responsive-element-binding protein by PI3 kinase and p38 MAPK is essential for elevated expression of transforming growth factor β2 in cancer cells. ( Kolattukudy, S; Lu, T; Stark, GR; Wan, Y; Yang, M, 2010) |
| "The metastasis suppressor breast cancer metastasis suppressor 1 (BRMS1) upregulates GJIC and decreases phosphoinositide-3-kinase (PI3K) signaling." | 1.36 | Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition. ( Beck, BH; Bodenstine, TM; Cook, LM; Diers, AR; Ismail, A; Landar, A; Vaidya, KS; Welch, DR, 2010) |
| "Refined cancer models are required if researchers are to assess the burgeoning number of potential targets for cancer therapeutics in a clinically relevant context that allows a fast turnaround." | 1.36 | Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia. ( Chow, JM; Khavari, PA; Ridky, TW; Wong, DJ, 2010) |
| "Thus, CQ is a very effective and cancer-specific chemosensitizer when used in combination with Akt inhibitors." | 1.35 | The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine. ( Hu, C; Lee, H; Solomon, VR; Ulibarri, G, 2008) |
| "We report here that both of these cancer cell lines express highly elevated levels of PLD activity and that the PLD activity is dependent upon Ras." | 1.34 | Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. ( Foster, DA; Garcia, A; Shi, M; Xu, L; Zheng, Y, 2007) |
| "Fifteen breast cancer cell lines and 92 primary breast tumors (33 with matched normal tissue) were used to check somatic mutation and gene copy number of PIK3CA." | 1.33 | Somatic mutation and gain of copy number of PIK3CA in human breast cancer. ( Chatterjee, A; Goldenberg, D; Gollin, SM; Guo, Z; Huang, X; Liu, J; Mambo, E; Sidransky, D; Sukumar, S; Trink, B; Wu, G; Xing, M, 2005) |
| "A COMPARE analysis of the National Cancer Institute chemical screening database revealed that the patterns of activity of PIAs correlated best with patterns of activity of other lipid-based compounds." | 1.33 | Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. ( Dennis, PA; Gills, JJ; Hewitt, SM; Holbeck, S; Hollingshead, M; Kozikowski, AP, 2006) |
| "Antiapoptotic activity of NF-kappaB in tumors contributes to acquisition of resistance to chemotherapy." | 1.32 | IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy. ( Bottero, V; Ikawa, M; Li, Q; Tergaonkar, V; Verma, IM, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (39.58) | 29.6817 |
| 2010's | 27 (56.25) | 24.3611 |
| 2020's | 2 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Hu, C | 1 |
| Solomon, VR | 1 |
| Ulibarri, G | 1 |
| Lee, H | 1 |
| Xia, Z | 1 |
| Knaak, C | 1 |
| Ma, J | 1 |
| Beharry, ZM | 1 |
| McInnes, C | 1 |
| Wang, W | 1 |
| Kraft, AS | 1 |
| Smith, CD | 1 |
| Finlay, MR | 1 |
| Griffin, RJ | 1 |
| Morrison, R | 1 |
| Al-Rawi, JM | 1 |
| Jennings, IG | 1 |
| Thompson, PE | 1 |
| Angove, MJ | 1 |
| Li, Y | 2 |
| Xiao, J | 1 |
| Zhang, Q | 1 |
| Yu, W | 1 |
| Liu, M | 1 |
| Guo, Y | 1 |
| He, J | 1 |
| Liu, Y | 1 |
| Myers, SH | 1 |
| Ortega, JA | 1 |
| Cavalli, A | 1 |
| Bansal, R | 1 |
| Malhotra, A | 1 |
| Song, L | 1 |
| Dong, X | 1 |
| Zhu, S | 1 |
| Zhang, C | 1 |
| Yin, W | 1 |
| Zhang, X | 1 |
| Liu, X | 1 |
| Gu, Z | 1 |
| Yu, G | 1 |
| Wang, C | 1 |
| Song, X | 1 |
| Liu, S | 1 |
| Zhang, Y | 2 |
| Fan, L | 1 |
| Yang, Y | 1 |
| Huang, Y | 2 |
| Song, J | 1 |
| Weingeist, DM | 1 |
| Ge, J | 1 |
| Wood, DK | 1 |
| Mutamba, JT | 1 |
| Huang, Q | 1 |
| Rowland, EA | 1 |
| Yaffe, MB | 1 |
| Floyd, S | 1 |
| Engelward, BP | 1 |
| Liu, PP | 1 |
| Liao, J | 1 |
| Tang, ZJ | 1 |
| Wu, WJ | 1 |
| Yang, J | 1 |
| Zeng, ZL | 1 |
| Hu, Y | 1 |
| Wang, P | 1 |
| Ju, HQ | 1 |
| Xu, RH | 1 |
| Huang, P | 1 |
| Rybalkina, EIu | 1 |
| Stromskaia, TP | 1 |
| Ovchinnikov, LP | 1 |
| Stavrovskaia, AA | 1 |
| Noh, KH | 1 |
| Kim, SH | 1 |
| Kim, JH | 1 |
| Song, KH | 1 |
| Lee, YH | 1 |
| Kang, TH | 1 |
| Han, HD | 1 |
| Sood, AK | 1 |
| Ng, J | 1 |
| Kim, K | 1 |
| Sonn, CH | 1 |
| Kumar, V | 1 |
| Yee, C | 1 |
| Lee, KM | 1 |
| Kim, TW | 1 |
| Ohoka, A | 1 |
| Kajita, M | 1 |
| Ikenouchi, J | 1 |
| Yako, Y | 1 |
| Kitamoto, S | 1 |
| Kon, S | 1 |
| Ikegawa, M | 1 |
| Shimada, T | 1 |
| Ishikawa, S | 1 |
| Fujita, Y | 2 |
| Wang, Q | 1 |
| Tan, R | 1 |
| Zhu, X | 1 |
| Tan, Z | 1 |
| Su, B | 1 |
| Hayashida, Y | 1 |
| Ikeda, Y | 1 |
| Sawada, K | 1 |
| Kawai, K | 1 |
| Kato, T | 1 |
| Kakehi, Y | 1 |
| Araki, N | 1 |
| Tsvetkov, D | 1 |
| Shymanets, A | 1 |
| Bucher, K | 1 |
| Piekorz, R | 1 |
| Hirsch, E | 1 |
| Beer-Hammer, S | 1 |
| Harteneck, C | 1 |
| Gollasch, M | 1 |
| Nürnberg, B | 1 |
| Zhang, XF | 1 |
| Sun, RQ | 1 |
| Jia, YF | 1 |
| Chen, Q | 1 |
| Tu, RF | 1 |
| Li, KK | 1 |
| Zhang, XD | 1 |
| Du, RL | 1 |
| Cao, RH | 1 |
| Kong, D | 2 |
| Yamori, T | 3 |
| Matsumoto, K | 1 |
| Arao, T | 1 |
| Tanaka, K | 1 |
| Kaneda, H | 1 |
| Kudo, K | 1 |
| Tamura, D | 1 |
| Aomatsu, K | 1 |
| Tamura, T | 1 |
| Yamada, Y | 1 |
| Saijo, N | 1 |
| Nishio, K | 1 |
| Dan, S | 1 |
| Yamazaki, K | 1 |
| Ward, CS | 1 |
| Venkatesh, HS | 1 |
| Chaumeil, MM | 1 |
| Brandes, AH | 1 |
| Vancriekinge, M | 1 |
| Dafni, H | 1 |
| Sukumar, S | 2 |
| Nelson, SJ | 1 |
| Vigneron, DB | 1 |
| Kurhanewicz, J | 1 |
| James, CD | 1 |
| Haas-Kogan, DA | 1 |
| Ronen, SM | 1 |
| David-Pfeuty, T | 1 |
| Legraverend, M | 1 |
| Ludwig, O | 1 |
| Grierson, DS | 1 |
| Zhao, P | 1 |
| Meng, Q | 1 |
| Liu, LZ | 1 |
| You, YP | 1 |
| Liu, N | 1 |
| Jiang, BH | 1 |
| Mireuta, M | 1 |
| Darnel, A | 1 |
| Pollak, M | 1 |
| Knight, ZA | 1 |
| Yang, JY | 1 |
| Chang, CJ | 1 |
| Xia, W | 1 |
| Wang, Y | 1 |
| Wong, KK | 1 |
| Engelman, JA | 1 |
| Du, Y | 1 |
| Andreeff, M | 1 |
| Hortobagyi, GN | 1 |
| Hung, MC | 1 |
| Wan, Y | 1 |
| Yang, M | 1 |
| Kolattukudy, S | 1 |
| Stark, GR | 1 |
| Lu, T | 1 |
| Bodenstine, TM | 1 |
| Vaidya, KS | 1 |
| Ismail, A | 1 |
| Beck, BH | 1 |
| Cook, LM | 1 |
| Diers, AR | 1 |
| Landar, A | 1 |
| Welch, DR | 1 |
| Ridky, TW | 1 |
| Chow, JM | 1 |
| Wong, DJ | 1 |
| Khavari, PA | 1 |
| Zhuang, L | 1 |
| Cao, Y | 1 |
| Xiong, H | 1 |
| Gao, Q | 1 |
| Cao, Z | 1 |
| Liu, F | 1 |
| Qiu, H | 1 |
| Yu, S | 1 |
| Huang, X | 2 |
| Jung, DW | 1 |
| Oh, ES | 1 |
| Park, SH | 1 |
| Chang, YT | 1 |
| Kim, CH | 1 |
| Choi, SY | 1 |
| Williams, DR | 1 |
| Beltran, L | 1 |
| Casado, P | 1 |
| Rodríguez-Prados, JC | 1 |
| Cutillas, PR | 1 |
| Nicholson, KM | 1 |
| Quinn, DM | 1 |
| Kellett, GL | 1 |
| Warr, JR | 1 |
| Tergaonkar, V | 1 |
| Bottero, V | 1 |
| Ikawa, M | 1 |
| Li, Q | 1 |
| Verma, IM | 1 |
| Yanamandra, N | 1 |
| Gumidyala, KV | 1 |
| Waldron, KG | 1 |
| Gujrati, M | 1 |
| Olivero, WC | 1 |
| Dinh, DH | 1 |
| Rao, JS | 1 |
| Mohanam, S | 1 |
| DeFeo-Jones, D | 1 |
| Barnett, SF | 1 |
| Fu, S | 1 |
| Hancock, PJ | 1 |
| Haskell, KM | 1 |
| Leander, KR | 1 |
| McAvoy, E | 1 |
| Robinson, RG | 1 |
| Duggan, ME | 1 |
| Lindsley, CW | 1 |
| Zhao, Z | 1 |
| Huber, HE | 1 |
| Jones, RE | 1 |
| Coffey, JC | 1 |
| Wang, JH | 1 |
| Smith, MJ | 1 |
| Laing, A | 1 |
| Bouchier-Hayes, D | 1 |
| Cotter, TG | 1 |
| Redmond, HP | 1 |
| Strickland, LA | 1 |
| Jubb, AM | 1 |
| Hongo, JA | 1 |
| Zhong, F | 1 |
| Burwick, J | 1 |
| Fu, L | 1 |
| Frantz, GD | 1 |
| Koeppen, H | 1 |
| Blanco-Aparicio, C | 1 |
| Pequeño, B | 1 |
| Moneo, V | 1 |
| Romero, L | 1 |
| Leal, JF | 1 |
| Velasco, J | 1 |
| Fominaya, J | 1 |
| Carnero, A | 1 |
| Wu, G | 1 |
| Xing, M | 1 |
| Mambo, E | 1 |
| Liu, J | 1 |
| Guo, Z | 1 |
| Chatterjee, A | 1 |
| Goldenberg, D | 1 |
| Gollin, SM | 1 |
| Trink, B | 1 |
| Sidransky, D | 1 |
| Gills, JJ | 1 |
| Holbeck, S | 1 |
| Hollingshead, M | 1 |
| Hewitt, SM | 1 |
| Kozikowski, AP | 1 |
| Dennis, PA | 1 |
| Akashi, T | 1 |
| Nishimura, Y | 1 |
| Wakatabe, R | 1 |
| Shiwa, M | 1 |
| Fujiwara, Y | 1 |
| Hosokawa, Y | 1 |
| Watanabe, K | 1 |
| Tanimura, S | 1 |
| Ozaki, K | 1 |
| Kohno, M | 1 |
| Bowers, RK | 1 |
| Marder, P | 1 |
| Green, LJ | 1 |
| Horn, CL | 1 |
| Faber, AL | 1 |
| Thomas, JE | 1 |
| Shi, M | 1 |
| Zheng, Y | 1 |
| Garcia, A | 1 |
| Xu, L | 1 |
| Foster, DA | 1 |
| Berrie, CP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single-Arm, Open-Label, Multi-Center, Phase I Study of YY-20394 in Patients With Advanced Solid Tumors[NCT04049929] | Phase 1 | 50 participants (Anticipated) | Interventional | 2019-08-31 | Not yet recruiting | ||
| A Phase I Study of YY-20394 Given Orally to Patients With Relapsed or Refractory B Cell Hematologic Malignancies[NCT03757000] | Phase 1 | 42 participants (Anticipated) | Interventional | 2017-12-25 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Benign Neoplasms
| Article | Year |
|---|---|
Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA; DNA Repair; DNA-Activated | 2012 |
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Pr | 2019 |
Synthetic Lethality through the Lens of Medicinal Chemistry.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cyclin-Dependent Kinases; DNA-Activated | 2020 |
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; | 2021 |
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
Topics: Androstadienes; Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Chromones; Combi | 2008 |
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
Topics: Androstadienes; Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Chromones; Combi | 2008 |
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
Topics: Androstadienes; Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Chromones; Combi | 2008 |
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
Topics: Androstadienes; Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Chromones; Combi | 2008 |
Small molecule inhibitors of the PI3-kinase family.
Topics: Adenine; Androstadienes; Animals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chrom | 2010 |
Phosphoinositide 3-kinase inhibition in cancer treatment.
Topics: Androstadienes; Animals; Chromones; Enzyme Inhibitors; Humans; Morpholines; Neoplasms; Phosphatidyli | 2001 |
41 other studies available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Benign Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cell Proliferation | 2008 |
Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell-Free System; Combinatorial Chemistry Techniques; Fem | 2009 |
Synthesis, structure elucidation, DNA-PK and PI3K and anti-cancer activity of 8- and 6-aryl-substituted-1-3-benzoxazines.
Topics: Antineoplastic Agents; Benzoxazines; Cell Line, Tumor; Cell Proliferation; DNA-Activated Protein Kin | 2016 |
Bi
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Bismuth; Cell Line, Tumor; Cell Survival; Chromones; | 2018 |
Formaldehyde induces the apoptosis of BMCs of BALB/c mice via the PTEN/PI3K/Akt signal transduction pathway.
Topics: Animals; Apoptosis; Bone Marrow Cells; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Ch | 2019 |
Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and DNA repair inhibitors.
Topics: Animals; Cell Line; CHO Cells; Chromones; Cricetinae; DNA Breaks, Double-Stranded; DNA Damage; DNA R | 2013 |
Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Sub | 2014 |
[Connection of intracellular protein YB-1 localization in cell cultures of human tumors with multidrug resistance].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2013 |
API5 confers tumoral immune escape through FGF2-dependent cell survival pathway.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; CD8-Positive T-Lymphocytes | 2014 |
EPLIN is a crucial regulator for extrusion of RasV12-transformed cells.
Topics: Animals; Butadienes; Caveolae; Caveolin 1; Cell Line; Cell Transformation, Neoplastic; Chromones; Co | 2015 |
Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Chromones; Dru | 2016 |
Invention of a novel photodynamic therapy for tumors using a photosensitizing PI3K inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chromones; Dose-Response Relationship, | 2016 |
Better Understanding of Phosphoinositide 3-Kinase (PI3K) Pathways in Vasculature: Towards Precision Therapy Targeting Angiogenesis and Tumor Blood Supply.
Topics: Androstadienes; Animals; Chromones; Class I Phosphatidylinositol 3-Kinases; Class Ib Phosphatidylino | 2016 |
Synthesis and mechanisms of action of novel harmine derivatives as potential antitumor agents.
Topics: A549 Cells; Animals; Antineoplastic Agents; Chromones; Harmine; HeLa Cells; Hep G2 Cells; Humans; Mi | 2016 |
mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells.
Topics: AC133 Antigen; Antigens, CD; Cell Line, Tumor; Chromones; Colorectal Neoplasms; Down-Regulation; Gly | 2009 |
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
Topics: Algorithms; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Chromones; Drug Screenin | 2010 |
Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.
Topics: Animals; Carbon Isotopes; Chromones; Drug Delivery Systems; Enzyme Inhibitors; Everolimus; Glioblast | 2010 |
Targeting the cell cycle and the PI3K pathway: a possible universal strategy to reactivate innate tumor suppressor programmes in cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Survival; Chromones; Cyc | 2010 |
Regulation of survivin by PI3K/Akt/p70S6K1 pathway.
Topics: Animals; Apoptosis; Cell Line, Tumor; Chick Embryo; Chromones; Enzyme Inhibitors; Gene Knockdown Tec | 2010 |
IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription.
Topics: Blotting, Western; Cell Line, Tumor; Chromones; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked I | 2010 |
Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer.
Topics: Animals; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Chlor | 2010 |
Activation of cAMP-responsive-element-binding protein by PI3 kinase and p38 MAPK is essential for elevated expression of transforming growth factor β2 in cancer cells.
Topics: Cell Line, Tumor; Chromones; CREB-Binding Protein; Cyclic AMP; Female; Humans; Imidazoles; Male; Mor | 2010 |
Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition.
Topics: Androstadienes; Cell Communication; Cell Line, Tumor; Cell Membrane; Chromones; Connexin 43; Cyclic | 2010 |
Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia.
Topics: Basement Membrane; Butadienes; Cell Transformation, Neoplastic; Chromones; Epithelial Cells; Gene Ex | 2010 |
Suppression of DNA-PKcs and Ku80 individually and in combination: Different effects of radiobiology in HeLa cells.
Topics: Antigens, Nuclear; Cell Cycle; Cell Line, Tumor; Chromones; DNA-Activated Protein Kinase; DNA-Bindin | 2011 |
A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Chromones; Dose-Response Relationsh | 2012 |
Global profiling of protein kinase activities in cancer cells by mass spectrometry.
Topics: Butadienes; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Humans; Morpholines; Neoplasm Proteins; | 2012 |
LY294002, an inhibitor of phosphatidylinositol-3-kinase, causes preferential induction of apoptosis in human multidrug resistant cells.
Topics: Apoptosis; Blotting, Western; Cell Line; Cell Survival; Chromones; Culture Media, Serum-Free; Drug R | 2003 |
IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy.
Topics: Animals; Base Sequence; Cells, Cultured; Chemotherapy, Adjuvant; Chromones; Cysteine Endopeptidases; | 2003 |
Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Biological Assay; Brain Neoplasms; Cathepsin B; Cell Line, Tumor; | 2004 |
Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antibiotics, Antineoplastic; Apoptosis; Caspase 3; Cas | 2005 |
Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Cell Li | 2005 |
Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF).
Topics: Carrier Proteins; Cell Line, Tumor; Cells, Cultured; Chromones; Endothelial Cells; Enzyme Inhibitors | 2005 |
Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria.
Topics: bcl-2-Associated X Protein; bcl-X Protein; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2005 |
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
Topics: Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Chro | 2005 |
Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chromones; Humans; Morpholines; Neoplas | 2006 |
Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Chromones; Dose-Response | 2007 |
Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated.
Topics: Antineoplastic Agents; Apoptosis; Cell Communication; Cell Differentiation; Chromones; Enzyme Inhibi | 2007 |
A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy.
Topics: Androstadienes; Animals; Blood Platelets; Chromones; Enzyme Inhibitors; Female; Flow Cytometry; Huma | 2007 |
Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Chromones; Culture Media, Serum-Free; Enzyme Activat | 2007 |